Safety and Immunogenicity of GSK2186877A Candidate Seasonal Influenza Vaccine in Healthy Children 6 to 35 Months of Age.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Influenza virus vaccine (Primary) ; AS03B; AS03C; AS03D
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 29 Dec 2010 Planned end date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 23 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.